CLASSIFICATION, PREVALENCE AND TREATMENT OF HEPACVIRIUS C
Keywords:
HCV, drugs, Ribavirin, interferon, antivirals, HepacivirusAbstract
Hepacivirus C has been remembered for the Flaviviridae family. It encompasses positive sense RNA infection and an individual from the Hepacivirus species. It's the overall issue and its predominance differs throughout the world while the greater part was in the USA however, now Egypt is the most influenced one. Its genotype varies because of the higher rate of recombination in the RNA genome. HCV significant transmission occurs due to blood transfusion. It can cause exhaustion, jaundice, anorexia, and numerous different diseases. It likewise impacts the liver if it’s in a persistent structure. Genotypes and subtypes are 8 and numerous (to be exact right around 126) individually. Genotype 1 has the most significant rate around the planet which influences around 40-80% of the population. USA has the most significant level of 1a and 1b, while in different nations genotype 1a isn't so normal. Pakistan has the most elevated level of HCV genotype 3a. Medicines have been built up that incorporate DAA (direct-acting antivirals), IFN-α (interferon alpha) Ribavirin, etc. A profoundly viable treatment is DAA. It may be utilized for the treatment of all age patients and the most elevated adequacy rate has been seen in youngsters because of DAA treatment. Interferon is given in a mix with other drugs. In recent years, practically half of the ongoing HCV-tainted patients have been restored with treatment other than DAA which includes ribavirin and interferon.
Downloads
References
Aghemo, A., and Colombo, M. J. G. (2014). Treatment of patients with dual hepatitis B and C: a step in the right direction. 63, 380-381.
Ahmad, I., Khan, S. B., ur Rehman, H., Khan, M. H., and Anwar, S. (2006). Frequency of Hepatitis B and Hepatitis C among cataract patients.
Alric, L., Fort, M., Izopet, J., Vinel, J., Charlet, J., Selves, J., Puel, J., Pascal, J., Duffaut, M., and Abbal, M. J. G. (1997). Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. 113, 1675-1681.
Altekruse, S. F., Henley, S. J., Cucinelli, J. E., and McGlynn, K. A. J. T. A. j. o. g. (2014). Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. 109, 542.
Alter, M. J. J. W. j. o. g. W. (2007). Epidemiology of hepatitis C virus infection. 13, 2436.
Amin, F., Hassan, N., Bashir, K., Khan, A., Bibi, H., Irshad, M., Khan, S., Nawaz, K., and Ullah, Z. (2023). Antimicrobial susceptibility profile of various bacteria isolated from respiratory tract infection. Bulletin of Biological and Allied Sciences Research 2023, 48-48.
Amjad, N., Rehman, M., Khalid, M., and Amjad, I. (2018). Construction of the infectious molecule of beta satellite associated with ageratum yellow vein disease of ageratum conyzoides. Bulletin of Biological and Allied Sciences Research 2018, 13-13.
Andre, P., Komurian-Pradel, F., Deforges, S., Perret, M., Berland, J., Sodoyer, M., Pol, S., Brechot, C., Paranhos-Baccala, G., and Lotteau, V. J. J. o. v. (2002). Characterization of low-and very-low-density hepatitis C virus RNA-containing particles. 76, 6919-6928.
Awan, S. J., Fatima, Z., Kamran, S., Khan, A. S., Fatima, T., Imran, S., Shabbir, M., and Nadeem, S. I. (2024). Guar gum in therapeutics: a succinct exploration. Bulletin of Biological and Allied Sciences Research 2024, 60.
Baid, S., Tolkoff‐Rubin, N., Saidman, S., Chung, R., Williams, W. W., Auchincloss, H., Colvin, R. B., Delmonico, F. L., Cosimi, A. B., and Pascual, M. J. A. J. o. T. (2003). Acute humoral rejection in hepatitis C‐infected renal transplant recipients receiving antiviral therapy. 3, 74-78.
Bartenschlager, R., Lohmann, V., and Penin, F. J. N. R. M. (2013). The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. 11, 482-496.
Bostan, N., and Mahmood, T. J. C. r. i. m. (2010). An overview about hepatitis C: a devastating virus. 36, 91-133.
Boulant, S., Vanbelle, C., Ebel, C., Penin, F., and Lavergne, J.-P. J. J. o. v. (2005). Hepatitis C virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features. 79, 11353-11365.
Brookman-May, S. D., Rodriguez-Faba, O., Langenhuijsen, J. F., Akdogan, B., Linares, E., Minervini, A., Klatte, T., Volpe, A., Brausi, M., and Marszalek, M. J. A. i. M. O. R. (2017). Challenges, hurdles and possible approaches to improve cancer care in developing countries–A short breakdown of the status quo and future perspective. 3, 204-212.
Cacoub, P., Poynard, T., Ghillani, P., Charlotte, F., Olivi, M., Charles Piette, J., Opolon, P. J. A., and Rheumatology, R. O. J. o. t. A. C. o. (1999). Extrahepatic manifestations of chronic hepatitis C. 42, 2204-2212.
Calattini, S., Fusil, F., Mancip, J., Thi, V. L. D., Granier, C., Gadot, N., Scoazec, J.-Y., Zeisel, M. B., Baumert, T. F., and Lavillette, D. J. J. o. B. C. (2015). Functional and biochemical characterization of hepatitis C virus (HCV) particles produced in a humanized liver mouse model. 290, 23173-23187.
Cancer, I. A. f. R. o. (2012). GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012.
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., and Houghton, M. J. S. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. 244, 359-362.
Colombo, M., Choo, Q., Del Ninno, E., Dioguardi, N., Kuo, G., Donato, M., Tommasini, M., and Houghton, M. J. T. L. (1989). Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. 334, 1006-1008.
Cooke, G., Lemoine, M., Thursz, M., Gore, C., Swan, T., Kamarulzaman, A., DuCros, P., and Ford, N. J. J. o. v. h. (2013). Viral hepatitis and the Global Burden of Disease: a need to regroup. 20, 600-601.
Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., and Albrecht, J. J. H. (2003). Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. 38, 645-652.
Dazert, E., Neumann-Haefelin, C., Bressanelli, S., Fitzmaurice, K., Kort, J., Timm, J., McKiernan, S., Kelleher, D., Gruener, N., and Tavis, J. E. J. T. J. o. c. i. (2009). Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27–restricted human immune response. 119, 376-386.
De Francesco, R., Tomei, L., Altamura, S., Summa, V., and Migliaccio, G. J. A. r. (2003). Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. 58, 1-16.
Dustin, L. B., Bartolini, B., Capobianchi, M. R., Pistello, M. J. C. m., and infection (2016). Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. 22, 826-832.
Fan, W., Zhu, W., Wei, L., Wang, Q., Yin, L., Du, S., and Zhuang, H. J. J. o. g. (2005). Nonstructural 5A gene variability of hepatitis C virus (HCV) during a 10-year follow up. 40, 43-51.
Feinstone, S. M., Kapikian, A. Z., Purcell, R. H., Alter, H. J., and Holland, P. V. J. N. E. J. o. M. (1975). Transfusion-associated hepatitis not due to viral hepatitis type A or B. 292, 767-770.
Finkelmeier, F., Dultz, G., Peiffer, K.-H., Kronenberger, B., Krauss, F., Zeuzem, S., Sarrazin, C., Vermehren, J., and Waidmann, O. J. L. C. (2018). Risk of de novo hepatocellular carcinoma after HCV treatment with direct-acting antivirals. 7, 190-204.
Fusaro, A., Monne, I., Salviato, A., Valastro, V., Schivo, A., Amarin, N. M., Gonzalez, C., Ismail, M. M., Al-Ankari, A.-R., and Al-Blowi, M. H. J. J. o. v. (2011). Phylogeography and evolutionary history of reassortant H9N2 viruses with potential human health implications. 85, 8413-8421.
Geddawy, A., Ibrahim, Y. F., Elbahie, N. M., and Ibrahim, M. A. J. J. o. t. i. m. (2017). Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction. 5, 8-17.
Gerresheim, G. K., Dünnes, N., Nieder-Röhrmann, A., Shalamova, L. A., Fricke, M., Hofacker, I., Zu Siederdissen, C. H., Marz, M., Niepmann, M. J. C., and sciences, m. l. (2017). microRNA-122 target sites in the hepatitis C virus RNA NS5B coding region and 3′ untranslated region: function in replication and influence of RNA secondary structure. 74, 747-760.
Gohar, M., Rehman, I., Ahmad, J., Ahmad, F., Bashir, K., Ikram, S., Hassan, N., Khan, M., and Ullah, A. (2023). Prevalence of hepatitis b virus and genotypes in the region of khyber pakhtunkhwa Pakistan. Bulletin of Biological and Allied Sciences Research 2023, 53-53.
Grakoui, A., McCourt, D., Wychowski, C., Feinstone, S., and Rice, C. J. J. o. v. (1993a). Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. 67, 2832-2843.
Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M., and Rice, C. M. J. P. o. t. N. A. o. S. (1993b). A second hepatitis C virus-encoded proteinase. 90, 10583-10587.
Greten, T., Papendorf, F., Bleck, J., Kirchhoff, T., Wohlberedt, T., Kubicka, S., Klempnauer, J., Galanski, M., and Manns, M. J. B. j. o. c. (2005). Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. 92, 1862-1868.
Griffin, S. D., Beales, L. P., Clarke, D. S., Worsfold, O., Evans, S. D., Jaeger, J., Harris, M. P., and Rowlands, D. J. J. F. l. (2003). The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. 535, 34-38.
Guerra, J., Garenne, M., Mohamed, M., and Fontanet, A. J. J. o. v. h. (2012). HCV burden of infection in Egypt: results from a nationwide survey. 19, 560-567.
Gutelius, B., Perz, J. F., Parker, M. M., Hallack, R., Stricof, R., Clement, E. J., Lin, Y., Xia, G.-L., Punsalang, A., and Eramo, A. J. G. (2010). Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. 139, 163-170.
Hagström, H. J. C. h. r. (2017). Alcohol consumption in concomitant liver disease: how much is too much? 16, 152-157.
Hajarizadeh, B., Grebely, J., Dore, G. J. J. N. r. G., and hepatology (2013). Epidemiology and natural history of HCV infection. 10, 553.
Hassan, N., Amin, F., Bashir, K., Irshad, M., Jamil, S., Munawar, N., Haqqani, H., Shabir, H., and Khan, M. (2023). Antiviral response of drugs used against hbv patients of Khyber Pakhtunkhwa, Pakistan. Bulletin of Biological and Allied Sciences Research 2023, 49-49.
Holz, L., and Rehermann, B. J. A. r. (2015). T cell responses in hepatitis C virus infection: historical overview and goals for future research. 114, 96-105.
Horner, S. M., and Gale, M. J. N. m. (2013). Regulation of hepatic innate immunity by hepatitis C virus. 19, 879-888.
Huang, H., Sun, F., Owen, D. M., Li, W., Chen, Y., Gale, M., and Ye, J. J. P. o. t. N. A. o. S. (2007). Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. 104, 5848-5853.
Jimenez, A. P., Eldin, N. S., Rimlinger, F., El-Daly, M., El-Hariri, H., El-Hoseiny, M., Mohsen, A., Mostafa, A., Delarocque-Astagneau, E., and Abdel-Hamid, M. J. G. (2010). HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. 59, 1554-1560.
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., and Sarnow, P. J. s. (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. 309, 1577-1581.
Karoney, M. J., and Siika, A. M. J. P. A. m. j. (2013). Hepatitis C virus (HCV) infection in Africa: a review. 14.
Kato, N. J. M., and genomics, c. (2000). Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. 5, 129-151.
Keating, G. M., and Vaidya, A. J. D. (2014). Sofosbuvir: first global approval. 74, 273-282.
Kenny-Walsh, E. J. N. E. J. o. M. (1999). Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. 340, 1228-1233.
Khan, N., Akmal, M., Hayat, M., Umar, M., Ullah, A., Ahmed, I., Rahim, K., Ali, S., Bahadar, S., and Saleha, S. J. H. m. (2014). Geographic distribution of hepatitis C virus genotypes in pakistan. 14.
Kokudo, N., Takemura, N., Hasegawa, K., Takayama, T., Kubo, S., Shimada, M., Nagano, H., Hatano, E., Izumi, N., and Kaneko, S. J. H. R. (2019). Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update. 49, 1109-1113.
Kramer, J. R., Kowalkowski, M. A., Duan, Z., and Chiao, E. Y. J. J. J. o. A. I. D. S. (2015). The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. 68, 456-462.
Krekulova, L., Řehák, V., and Riley, L. J. F. m. (2006). Structure and functions of hepatitis C virus proteins: 15 years after. 51, 665-680.
Kruse, R. L., Kramer, J. R., Tyson, G. L., Duan, Z., Chen, L., El‐Serag, H. B., and Kanwal, F. J. H. (2014). Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus‐infected patients. 60, 1871-1878.
Lamoury, F. M., Bajis, S., Hajarizadeh, B., Marshall, A. D., Martinello, M., Ivanova, E., Catlett, B., Mowat, Y., Marks, P., and Amin, J. J. T. J. o. i. d. (2018). Evaluation of the Xpert HCV viral load finger-stick point-of-care assay. 217, 1889-1896.
Laperche, S., and Transfusion, F. A. G. f. R. i. B. T. J. (2013). Multinational assessment of blood‐borne virus testing and transfusion safety on the African continent. 53, 816-826.
Lavanchy, D. J. C. M., and Infection (2011). Evolving epidemiology of hepatitis C virus. 17, 107-115.
Lok, A. S., Seeff, L. B., Morgan, T. R., Di Bisceglie, A. M., Sterling, R. K., Curto, T. M., Everson, G. T., Lindsay, K. L., Lee, W. M., and Bonkovsky, H. L. J. G. (2009). Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. 136, 138-148.
Lundin, M., Lindström, H., Grönwall, C., and Persson, M. A. J. J. o. g. v. (2006). Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein. 87, 3263-3272.
Maggi, F., Focosi, D., and Pistello, M. J. C. d. t. (2017). How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection? 18, 811-825.
Magiorkinis, G., Magiorkinis, E., Paraskevis, D., Ho, S. Y., Shapiro, B., Pybus, O. G., Allain, J.-P., and Hatzakis, A. J. P. M. (2009). The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. 6, e1000198.
Mahale, P., Torres, H. A., Kramer, J. R., Hwang, L. Y., Li, R., Brown, E. L., and Engels, E. A. J. C. (2017). Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry‐based case‐control study. 123, 1202-1211.
Mancebo, A., González–Diéguez, M. L., Cadahía, V., Varela, M., Pérez, R., Navascués, C. A., Sotorríos, N. G., Martínez, M., Rodrigo, L., Rodríguez, M. J. C. g., and hepatology (2013). Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. 11, 95-101.
Marcellin, P. J. L. I. (2009). Hepatitis B and hepatitis C in 2009. 29, 1-8.
Margraf, R. L., Erali, M., Liew, M., and Wittwer, C. T. J. J. o. c. m. (2004). Genotyping hepatitis C virus by heteroduplex mobility analysis using temperature gradient capillary electrophoresis. 42, 4545-4551.
McLauchlan, J. J. J. o. v. h. (2000). Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. 7, 2-14.
Murphy, D. G., Willems, B., Deschênes, M., Hilzenrat, N., Mousseau, R., and Sabbah, S. J. J. o. c. m. (2007). Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. 45, 1102-1112.
Nouroz, F., Shaheen, S., Mujtaba, G., and Noreen, S. J. E. J. o. M. H. G. (2015). An overview on hepatitis C virus genotypes and its control. 16, 291-298.
Obaid, A., Ahmad, J., Naz, A., Awan, F. M., Paracha, R. Z., Tareen, S. H. K., Anjum, S., Raza, A., Baumbach, J., and Ali, A. J. I. B. (2015). Modeling and analysis of innate immune responses induced by the host cells against hepatitis C virus infection. 7, 544-559.
Okuda, M., Li, K., Beard, M. R., Showalter, L. A., Scholle, F., Lemon, S. M., and Weinman, S. A. J. G. (2002). Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. 122, 366-375.
Patel, P. R., Larson, A. K., Castel, A. D., Ganova-Raeva, L. M., Myers, R. A., Roup, B. J., Farrell, K. P., Edwards, L., Nainan, O., and Krick, J. P. J. J. (2006). Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies. 296, 2005-2011.
Paul, D., Madan, V., Bartenschlager, R. J. C. h., and microbe (2014). Hepatitis C virus RNA replication and assembly: living on the fat of the land. 16, 569-579.
Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A., and Cacciapuoti, C. J. W. j. o. g. (2016). Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. 22, 7824.
Pietschmann, T., Kaul, A., Koutsoudakis, G., Shavinskaya, A., Kallis, S., Steinmann, E., Abid, K., Negro, F., Dreux, M., and Cosset, F.-L. J. P. o. t. N. A. o. S. (2006). Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. 103, 7408-7413.
Prati, D. J. J. o. h. (2006). Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. 45, 607-616.
Puchades Renau, L., and Berenguer, M. J. H. I. (2018). Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies. 22, S8-S21.
Quan, V. M., Go, V. F., Nam, L. V., Bergenstrom, A., Thuoc, N. P., Zenilman, J., Latkin, C., and Celentano, D. D. J. A. c. (2009). Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case–control study. 21, 7-16.
Raja, N. S., Janjua, K. A. J. J. o. M., Immunology,, and Infection (2008). Epidemiology of hepatitis C virus infection in Pakistan. 41, 4-8.
Rauf, A., Nadeem, M. S., Ali, A., Iqbal, M., Mustafa, M., Muzammal Latif, M., Latif, M. Z., Ahmed, N., and Shakoori, A. R. J. T. E. J. o. P. H. (2011). Prevalence of hepatitis B and C in internally displaced persons of war against terrorism in Swat, Pakistan. 21, 638-642.
Report, W. H. O. J. S. (2011). Global database on blood safety. 2011, 3-4.
Roberts, E. A., and Yeung, L. J. H. (2002). Maternal‐infant transmission of hepatitis C virus infection. 36, S106-S113.
Rosa, D., Campagnoli, S., Moretto, C., Guenzi, E., Cousens, L., Chin, M., Dong, C., Weiner, A. J., Lau, J., and Choo, Q.-L. J. P. o. t. N. A. o. S. (1996). A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. 93, 1759-1763.
Santolini, E., Pacini, L., Fipaldini, C., Migliaccio, G., and Monica, N. J. J. o. v. (1995). The NS2 protein of hepatitis C virus is a transmembrane polypeptide. 69, 7461-7471.
Scheel, T. K., Gottwein, J. M., Jensen, T. B., Prentoe, J. C., Hoegh, A. M., Alter, H. J., Eugen-Olsen, J., and Bukh, J. J. P. o. t. N. A. o. S. (2008). Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. 105, 997-1002.
Scheel, T. K., and Rice, C. M. J. N. m. (2013). Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. 19, 837-849.
Schoggins, J. W., and Rice, C. M. J. H. C. V. F. M. V. t. A. T. (2013). Innate immune responses to hepatitis C virus. 219-242.
Schulze-Krebs, A., Preimel, D., Popov, Y., Bartenschlager, R., Lohmann, V., Pinzani, M., and Schuppan, D. J. G. (2005). Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. 129, 246-258.
Sheahan, T., Imanaka, N., Marukian, S., Dorner, M., Liu, P., Ploss, A., Rice, C. M. J. C. h., and microbe (2014). Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. 15, 190-202.
Sheema, Bashir, K., Fiaz, S., Khan, A. W., Haqqani, S., Bibi, A., Nawaz, K., Khan, M. A., and Ullah, A. (2024). Molecular identification of hcv genotypes among injecting drug users having HCV and HIV co-infection. Bulletin of Biological and Allied Sciences Research 2024, 71.
Shekhar, S. (2018). Hepatitis C Virus Infection in the Indian Sub-Continent. In "Hepatitis C in Developing Countries", pp. 83-95. Elsevier.
Shimakami, T., Yamane, D., Jangra, R. K., Kempf, B. J., Spaniel, C., Barton, D. J., and Lemon, S. M. J. P. o. t. N. A. o. S. (2012). Stabilization of hepatitis C virus RNA by an Ago2–miR-122 complex. 109, 941-946.
Sievert, W., Altraif, I., Razavi, H. A., Abdo, A., Ahmed, E. A., AlOmair, A., Amarapurkar, D., Chen, C. H., Dou, X., and El Khayat, H. J. L. i. (2011). A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. 31, 61-80.
Simmonds, P. J. J. o. G. V. (2004). Genetic diversity and evolution of hepatitis C virus–15 years on. 85, 3173-3188.
Smith, D. B., Bukh, J., Kuiken, C., Muerhoff, A. S., Rice, C. M., Stapleton, J. T., and Simmonds, P. J. H. (2014). Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. 59, 318-327.
Stanaway, J. D., Flaxman, A. D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., Abu-Raddad, L. J., Assadi, R., Bhala, N., and Cowie, B. J. T. L. (2016). The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. 388, 1081-1088.
Steinmann, E., Penin, F., Kallis, S., Patel, A. H., Bartenschlager, R., and Pietschmann, T. J. P. P. (2007). Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. 3, e103.
Strader, D. B., and Seeff, L. B. J. C. L. D. (2012). A brief history of the treatment of viral hepatitis C. 1, 6-11.
Tagny, C. T., Mbanya, D., Tapko, J. B., and Lefrère, J. J. J. T. (2008). Blood safety in Sub‐Saharan Africa: a multi‐factorial problem. 48, 1256-1261.
Te, H. S., Randall, G., Jensen, D. M. J. G., and hepatology (2007). Mechanism of action of ribavirin in the treatment of chronic hepatitis C. 3, 218.
Terrault, N. A. J. H. (2002). Sexual activity as a risk factor for hepatitis C. 36, S99-S105.
Thein, H. H., Yi, Q., Dore, G. J., and Krahn, M. D. J. H. (2008). Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: a meta‐analysis and meta‐regression. 48, 418-431.
Thompson, N. D., Perz, J. F., Moorman, A. C., and Holmberg, S. D. J. A. o. I. M. (2009). Nonhospital health care–associated hepatitis B and C virus transmission: United States, 1998–2008. 150, 33-39.
Tomasetti, C., Li, L., and Vogelstein, B. J. S. (2017). Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. 355, 1330-1334.
Tong, M. J., El-Farra, N. S., Reikes, A. R., and Co, R. L. J. N. E. J. o. M. (1995). Clinical outcomes after transfusion-associated hepatitis C. 332, 1463-1466.
Turner, K. M., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N., May, M., Taylor, A., De Angelis, D., and Cameron, S. J. A. (2011). The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. 106, 1978-1988.
Ullah, I., Ullah, A., Rehman, S., Ullah, S., Ullah, H., Haqqni, S., Amir, M., Gul, F., and Bashir, K. (2023). Prevalence and risk factors of helicobacter pylori infection among individuals with tobacco consumption habits in district Peshawar: a cross-sectional study. Bulletin of Biological and Allied Sciences Research 2023, 42-42.
van de Laar, T. J., Matthews, G. V., Prins, M., and Danta, M. J. A. (2010). Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. 24, 1799-1812.
Velati, C., Romanò, L., Baruffi, L., Pappalettera, M., Carreri, V., and Zanetti, A. R. J. T. (2002). Residual risk of transfusion‐transmitted HCV and HIV infections by antibody‐screened blood in Italy. 42, 989-993.
Vescovo, T., Refolo, G., Vitagliano, G., Fimia, G. M., Piacentini, M. J. C. M., and Infection (2016). Molecular mechanisms of hepatitis C virus–induced hepatocellular carcinoma. 22, 853-861.
Wang, H., Naghavi, M., Allen, C., Barber, R., Carter, A., Casey, D., Charlson, F., Chen, A., Coates, M., and Coggeshall, M. J. T. L. (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â 2015: a systematic analysis for the Global Burden of Disease Study 2015. 388, 1459-1544.
Wieland, S., Makowska, Z., Campana, B., Calabrese, D., Dill, M. T., Chung, J., Chisari, F. V., and Heim, M. H. J. H. (2014). Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. 59, 2121-2130.
Wölk, B., Sansonno, D., Kräusslich, H.-G., Dammacco, F., Rice, C. M., Blum, H. E., and Moradpour, D. J. J. o. v. (2000). Subcellular localization, stability, andtrans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. 74, 2293-2304.
Yamaga, A. K., and Ou, J.-h. J. J. o. B. C. (2002). Membrane topology of the hepatitis C virus NS2 protein. 277, 33228-33234.
Yang, J. D., and Roberts, L. R. J. I. D. C. (2010). Epidemiology and management of hepatocellular carcinoma. 24, 899-919.
Zeisel, M. B., Felmlee, D. J., and Baumert, T. F. J. H. C. V. F. M. V. t. A. T. (2013). Hepatitis C virus entry. 87-112.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2024 HMU HASSAN, T ZIA, S ISHAQ, A ULLAH (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
